Parties will share information and consult on their programs.

The Global Alliance for TB Drug Development and sanofi-aventis are joining forces to discover and develop medications that will shorten treatment and be effective against drug-susceptible and drug-resistant strains of TB.

The two organizations will share information on their respective R&D projects. They will also consult with each other on regulatory, access, and clinical trial strategies related to developing countries.

The TB Alliance reports that it has two candidates in clinical trials and 12 others in its pipeline. Sanofi-aventis markets anti-TB drugs and is researching new approaches including vaccines and drug compounds with new mechanisms of action.

Previous articlePharma and Biotech Will Follow the Rest of the Economic Downward Trend – a Defensive Play no Longer
Next articleSynta Achieves $25M Milestone in Cancer Deal with GSK